Summary

Introduction to Europe Hematologic Malignancies Testing Market

The Europe hematologic malignancies testing market was valued at $921.3 million in 2024 and is expected to reach $2,620.8 million by 2033, growing at a CAGR of 12.32% during the forecast period 2024-2033. Detecting and tracking blood cancers like leukemia, lymphoma, and myeloma is the primary focus of the Europe Hematologic Malignancies Testing Market. The market is expanding significantly due to the increasing incidence of these malignancies and ongoing technological advancements. Key diagnostic technologies are essential for accurate diagnosis, prognosis, and personalized treatment planning. These technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry.

A rise in clinical research and trials, the growing burden of hematologic cancers, and the growing demand for precise diagnostic solutions are the main factors propelling the market's growth. The demand for hematologic malignancy testing kits and services is also being driven by increased government funding and healthcare initiatives that support early detection and treatment. Continuous developments in molecular diagnostics have produced more innovative and effective testing solutions.
Additionally, the expansion of testing accessibility through hospitals, specialized diagnostic centers, and online healthcare platforms is improving patient access across Europe. As precision medicine and targeted therapies gain traction, the demand for hematologic malignancy testing is expected to rise, fostering market growth across the region.

Market Introduction

The Europe Hematologic Malignancies Testing Market is expanding rapidly due to the increasing prevalence of blood cancers such as leukemia, lymphoma, and multiple myeloma. Developments in diagnostic technologies, including flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunohistochemistry, are improving prognosis, treatment planning, and early detection.

Growing demand for personalized medicine, expanding clinical trials, and increased research activities are important market drivers. Further propelling market expansion are government programs and healthcare investments targeted at early cancer detection. Market expansion is also being influenced by the use of liquid biopsy for minimal residual disease (MRD) monitoring and the incorporation of artificial intelligence (AI) in genomic testing.

The Europe Hematologic Malignancies Testing Market is expected to grow steadily due to the growing use of precision medicine and the expanded accessibility of testing options via online and hospital platforms, which will enhance patient outcomes and treatment approaches throughout the region.

Market Segmentation:

Segmentation 1: by Product
• Kits
• Services

Segmentation 2: by Platform
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Platforms

Segmentation 3: by Disease
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Myelodysplastic Syndrome

Segmentation 4: by End User
• Specialty Clinics and Hospitals
• Diagnostic Laboratories
• Reference Laboratories

Segmentation 5: by Region
• Germany
• U.K.
• France
• Italy
• Spain
• Denmark
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe hematologic malignancies testing market has been segmented based on various categories, such as products, platforms, diseases, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe hematologic malignancies testing market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Europe hematologic malignancies testing market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• F. Hoffmann-La Roche Ltd.
• ICON plc
• QIAGEN N.V.
• DiaSorin S.p.A
• ELITech Group

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
1 Europe Hematologic Malignancies Testing Market: Market Overview
1.1 Introduction
1.2 Types of Hematologic Malignancies Diagnostic Tests
1.3 Market Footprint and Growth Potential
2 Hematologic Malignancies Testing Market: Industry Analysis
2.1 Key Trends: Current and Future Impact Assessment
2.1.1 Growing Utilization of Next-Generation Sequencing and Artificial Intelligence in Hematologic Malignancies Testing
2.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
2.2 Regulatory Framework
2.2.1 Regulatory Framework in Europe
2.3 COVID-19's Impact on Cancer Diagnostic Market
2.4 Supply Chain Analysis
2.4.1 Key Entities in Supply Chain
2.5 Pricing Analysis
2.6 Comparative Analysis of Hematologic Malignancies Test by Different Parameters
3 Region
3.1 Regional Summary
3.2 Drivers and Restraints
3.3 Europe
3.3.1 Regional Overview
3.3.2 Driving Factors for Market Growth
3.3.3 Factors Challenging the Market
3.3.4 Germany
3.3.5 U.K.
3.3.6 Spain
3.3.7 Italy
3.3.8 France
3.3.9 Denmark
3.3.10 Rest-of-Europe
4 Europe Hematologic Malignancies Testing Market - Competitive Benchmarking and Company Profiles
4.1 Key Strategies and Development
4.1.1 Partnerships, Alliances, and Business Expansions
4.1.2 Regulatory and Legal Activities
4.1.3 New Offerings
4.1.4 Mergers and Acquisitions
4.2 Market Share
4.3 Company Profiles
4.3.1 F. Hoffmann-La Roche Ltd.
4.3.1.1 Overview
4.3.1.2 Top Products
4.3.1.3 Top Competitors
4.3.1.4 Key Customers
4.3.1.5 Key Personnel
4.3.1.6 Corporate Strategies
4.3.1.7 Analyst View
4.3.2 ICON plc
4.3.2.1 Overview
4.3.2.2 Top Products
4.3.2.3 Top Competitors
4.3.2.4 Top Customers
4.3.2.5 Key Personnel
4.3.2.6 Analyst View
4.3.3 QIAGEN N.V.
4.3.3.1 Overview
4.3.3.2 Top Products
4.3.3.3 Top Competitors
4.3.3.4 Top Customers
4.3.3.5 Key Personnel
4.3.3.6 Corporate Strategies
4.3.3.7 Analyst View
4.3.4 DiaSorin S.p.A
4.3.4.1 Overview
4.3.4.2 Top Products
4.3.4.3 Top Competitors
4.3.4.4 Top Customers
4.3.4.5 Key Personnel
4.3.4.6 Corporate Strategies
4.3.4.7 Analyst View
4.3.5 ELITech Group
4.3.5.1 Overview
4.3.5.2 Top Products
4.3.5.3 Top Competitors
4.3.5.4 Top Customers
4.3.5.5 Analyst View
5 Research Methodology
5.1 Data Sources
5.1.1 Primary Data Sources
5.1.2 Secondary Data Sources
5.1.3 Data Triangulation
List of Figures
Figure 1: Europe Hematologic Malignancies Testing Market, $Million, 2024, 2028 and 2033
Figure 2: Hematologic Malignancies Testing Market (by Region), $Million, 2023, 2027, and 2033
Figure 3: Europe Hematologic Malignancies Testing Market (by Product), $Million, 2023, 2027, and 2033
Figure 4: Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2023, 2027, and 2033
Figure 5: Europe Hematologic Malignancies Testing Market (by Disease), $Million, 2023, 2027, and 2033
Figure 6: Europe Hematologic Malignancies Testing Market (by End User), $Million, 2023, 2027, and 2033
Figure 7: Europe Hematologic Malignancies Testing Market, Recent Developments
Figure 8: Classification of Hematologic Malignancies
Figure 9: Europe Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 10: Hematologic Malignancies Testing Market Vs TAM, 2022-2033
Figure 11: Share of Partnerships, Alliances, and Business Expansions vs. Other Strategies
Figure 12: Some of the Key Partnerships, Alliances, and Business Expansions and their Impact on the Global Sequencing Market
Figure 13: Workflow for the IVD Product Approval
Figure 14: Medical Research Cycle Interruption during the COVID-19 Pandemic
Figure 15: Hematologic Malignancies Testing Supply Chain Analysis
Figure 16: Germany Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 17: Germany Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 18: U.K. Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 19: U.K. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 20: Spain Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 21: Spain Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 22: Italy Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 23: Italy Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 24: France Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 25: France Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 26: Denmark Hematologic Malignancies Testing Market, $Million, 2022-2033
Figure 27: Denmark. Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 28: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume, Thousands, 2022-2033
Figure 29: Partnerships, Alliances, and Business Expansions Activities, January 2020-May 2024
Figure 30: Regulatory and Legal Activities, January 2020-May 2024
Figure 31: New Offerings, January 2020-May 2024
Figure 32: Mergers and Acquisitions, January 2020-May 2024
Figure 33: Europe Hematologic Malignancies Testing Market, Market Share (by Company)
Figure 34: Data Triangulation
Figure 35: Assumptions and Limitations
List of Tables
Table 1: Market Snapshot
Table 2: Hematologic Malignancies Testing Market, Market Opportunities
Table 3: Diagnostic Tests for Hematologic Malignancies
Table 4: Current and Future Impact of Trends
Table 5: Effect of COVID-19 on Cancer Care throughout the World
Table 6: Pricing Analysis (by Platform Testing)
Table 7: Comparative Analysis of Hematologic Malignancies Test
Table 8: Hematologic Malignancies Testing Market (by Region), $Million, 2022-2033
Table 9: Hematologic Malignancies Testing Market (by Country), $Million, 2022-2033
Table 10: Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 11: Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 12: Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 13: Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 14: Germany Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 15: Germany Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 16: Germany Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 17: Germany Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 18: Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 19: Germany Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 20: Germany Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 21: U.K. Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 22: U.K. Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 23: U.K. Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 24: U.K. Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 25: U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 26: U.K. Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 27: U.K. Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 28: Spain Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 29: Spain Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 30: Spain Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 31: Spain Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 32: Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 33: Spain Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 34: Spain Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 35: Italy Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 36: Italy Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 37: Italy Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 38: Italy Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 39: Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 40: Italy Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 41: Italy Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 42: France Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 43: France Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 44: France Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 45: France Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 46: France Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 47: France Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 48: France Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 49: Denmark Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 50: Denmark Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 51: Denmark Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 52: Denmark Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 53: Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 54: Denmark Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 55: Denmark Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 56: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2022-2033
Table 57: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Platform), Thousands, 2022-2033
Table 58: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by Diseases), Thousands, 2022-2033
Table 59: Rest-of-Europe Hematologic Malignancies Testing Market, Test Volume (by End User), Thousands, 2022-2033
Table 60: Rest-of-Europe Hematologic Malignancies Testing Market (by Product), $Million, 2022-2033
Table 61: Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2022-2033
Table 62: Rest-of-Europe Hematologic Malignancies Testing Market (by Diseases), $Million, 2022-2033
Table 63: Rest-of-Europe Hematologic Malignancies Testing Market (by End User), $Million, 2022-2033
Table 64: Europe Hematologic Malignancies Testing Market, Key Development Analysis, January 2020-May 2024

Press Release